Linical Co., Ltd., a global contract research organization, provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug discovery consulting services, such as market analysis and research of products in development, regulatory affairs, and licensing support. It also provides clinical trial evaluation, statistical analysis, medical writing, pharmacovigilance, clinical monitoring, and contract medical affairs services. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Frequently asked questions
What sector does Linical Co Ltd (2183) operate in?
Linical Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Linical Co Ltd (2183) current stock price?
As of the latest data, Linical Co Ltd stock price is ¥204, with a previous close of ¥210. Linical Co Ltd lost -¥6 in the last trading session, representing a -2.86% loss.
What is Linical Co Ltd (2183) current market capitalization?
Linical Co Ltd market cap is approximately 4.61 billion.
What is Linical Co Ltd (2183) Earnings Per Share (EPS)?
The trailing EPS is -¥147.
What is Linical Co Ltd (2183) EBITDA?
Linical Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -640.61 million.
Does Linical Co Ltd (2183) pay dividends?
Yes. Linical Co Ltd pays annual dividends with an annualized yield of 3.92% and an estimated annual payout of ¥8 per share.
When is the next ex-dividend date for Linical Co Ltd (2183)?
The next ex-dividend date is scheduled for March 30, 2027.
What is Linical Co Ltd (2183) beta (volatility) score?
Linical Co Ltd has a beta of 0.384, indicating lower volatility than the overall market.